---

Labetalol in Obstetric Practice — A Comprehensive Guide for PG Residents

---

1. Pharmacology & Mechanism of Action

• Reduces systemic vascular resistance (via α₁ blockade) → lowers BP
• Blunts reflex tachycardia (via β blockade) → stable maternal heart rate
• Preserves placental blood flow — uteroplacental perfusion is maintained, unlike pure vasodilators that cause reflex tachycardia
• Preserves maternal cardiac output
• No significant sympathetic blockade in the neonate at standard doses

---

2. Clinical Indications in Obstetrics

A. Chronic Hypertension in Pregnancy (Antepartum)

"α-Methyldopa and labetalol, an α- and β-blocker, are the two most commonly used drugs for treatment of chronic hypertension in pregnancy." — Textbook of Family Medicine, 9e

• Starting dose: 100–200 mg orally twice daily
• Titration: Up to 400–800 mg three times daily (maximum ~2400 mg/day)
• The target: maintain diastolic BP < 100–105 mmHg; avoid sudden drops to protect uteroplacental flow

• Diastolic BP persistently > 100–105 mmHg, OR
• Systolic BP > 160 mmHg

"Other drugs with reasonable evidence of safety also may be used, including the combination α₁-selective, β-nonselective adrenergic antagonist labetalol (100 mg twice daily)." — Goodman & Gilman's Pharmacological Basis of Therapeutics

---

B. Acute Severe Hypertension / Hypertensive Emergency in Pregnancy & Postpartum

"Intravenous labetalol and hydralazine and oral nifedipine are considered first-line treatments." — Creasy & Resnik's Maternal-Fetal Medicine, Principles and Practice

IV Labetalol Protocol (ACOG/Standard):

• If max dose of labetalol is reached without adequate control → switch to hydralazine or nicardipine infusion
• ACOG recommends emergent MFM/anesthesiology consult if first-line agents fail

"Protocols for progressive intravenous labetalol or hydralazine, or oral nifedipine, are described... National guidelines now recommend aggressive treatment of systolic hypertension greater than 160 mmHg or diastolic hypertension greater than 110 mmHg, if confirmed as persistent for 15 minutes or more." — Creasy & Resnik's Maternal-Fetal Medicine

---

C. Preeclampsia with Severe Features

• BP control threshold: SBP ≥ 160 or DBP ≥ 110 mmHg
• Magnesium sulfate: 4–6 g IV loading dose → 2 g/hr maintenance (NOT labetalol — this is for seizure prophylaxis)
• Undertreated hypertension is the primary risk factor for intracranial haemorrhage (93% of associated strokes are hemorrhagic; 54% mortality)

---

D. Eclampsia (Postseizure Antihypertensive)

• Diastolic BP remains > 105 mmHg, OR
• Systolic BP remains > 160 mmHg

---

3. Comparison with Other First-Line Agents

---

4. Contraindications

Practical tip for residents: Always auscultate the chest before giving labetalol. A patient with wheeze requires nifedipine or hydralazine instead.

---

5. Adverse Effects

Maternal:

• Postural hypotension (especially after IV doses — keep patient supine for 3 hrs post-IV)
• Bradycardia
• Nausea, vomiting, scalp tingling (paraesthesia)
• Hepatotoxicity (rare, with prolonged oral use — monitor LFTs)
• Fatigue

Fetal/Neonatal:

• IUGR — reported with prolonged use near delivery
• Neonatal bradycardia and hypoglycaemia — due to β-blockade. Neonates should be monitored for 24–48 hours after delivery if mother received labetalol near term

"Newborn should be screened/monitored for 24–48 hr for symptoms of beta blockade." — Rosen's Emergency Medicine, 10e

• Respiratory distress (rare, from β₂ blockade)
• Neonatal hypotension

---

6. Use in Special Situations

Intrapartum (During Labour)

• Continue if patient was on oral labetalol antepartum
• Monitor maternal BP and fetal heart rate continuously
• Epidural analgesia is compatible — labetalol does not contraindicate regional anaesthesia

Postpartum

• Continue antihypertensive treatment — approximately 20% of eclampsia episodes occur > 48 hours after delivery
• BP may initially rise 3–6 days postpartum (rebound from vasoconstriction resolution)
• Threshold for treatment postpartum: same as antepartum (SBP ≥ 160 or DBP ≥ 110 mmHg)
• A 2025 meta-analysis (PMID 40914007) found no significant difference in postpartum readmission risk between labetalol and nifedipine

Breastfeeding

• Compatible with breastfeeding — excreted in breast milk in very small amounts
• AAP considers it acceptable
• Monitor neonate for bradycardia and hypotension

Anaesthesia for Caesarean Section

• Labetalol (or esmolol) can be used to attenuate the hypertensive response to laryngoscopy in preeclamptic patients requiring general anaesthesia
• Remifentanil 1–2 mcg/kg is an alternative

---

7. Key Points for Postgraduate Exam & Clinical Practice

---

Sources

• Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice (Chapters 45, 70, 76)
• Goodman & Gilman's Pharmacological Basis of Therapeutics — Drug Therapy in Obstetrics
• Textbook of Family Medicine, 9e — Chronic Hypertension in Pregnancy
• Rosen's Emergency Medicine, 10e — Preeclampsia/Eclampsia Management; Table 175.8
• Li L et al. "Oral nifedipine versus intravenous labetalol for hypertensive emergencies during pregnancy." J Matern Fetal Neonatal Med. 2023 Dec. [PMID: 37487762]
• Gonçalves OR et al. "Comparative efficacy and safety between IV labetalol and IV hydralazine for hypertensive disorders in pregnancy: systematic review and meta-analysis of 19 RCTs." Eur J Obstet Gynecol Reprod Biol. 2024 Dec. [PMID: 39522185]
• Kanninen T et al. "Risk of postpartum readmission following discharge on nifedipine or labetalol for hypertensive disorders." Eur J Obstet Gynecol Reprod Biol. 2025 Nov. [PMID: 40914007]